At the same time, another related study indicated that CSF CHI3L1 is not a pre-biomarker for early symptoms of AD, which makes measuring AD progression by measuring CHI3L1 levels in CSF seem unreliable. The gene discussed is CHI3L1; the disease is Alzheimer disease.